The Research and Development team at EpimAb Biotherapeutics focuses on the innovation and advancement of bi-specific antibody technologies. This multidisciplinary team collaborates on the design, testing, and validation of novel biopharmaceutical candidates, ensuring their safety and efficacy through rigorous nonclinical and clinical development processes. By integrating expertise across biology, toxicology, and clinical strategy, the team aims to accelerate the delivery of cutting-edge therapeutics to the market.